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ABSTRACT 
Title: Intraoperative Lidocaine Infusions for Postoperative Pain Management 
Background: It is known that postoperative pain is a significant cause for patient dissatisfaction 
following many types of surgery. Anesthesia professionals search for ways to treat pain from a 
multi-modal approach, however postoperative pain continues to be a surgical complication. 
Lidocaine infusions have been studied over the last two decades, and although literature has been 
controversial for certain surgical populations, research continues to advocate for its use in 
anesthesia. Lidocaine has been found to be a potent analgesic, anti-inflammatory, and anti-
hyperalgesia medication that is safe and inexpensive. By reducing the use of opioids and 
incorporating lidocaine infusions into practice, patients can achieve better postoperative pain 
scores and avoid undesirable side effects such as respiratory depression, sedation, nausea, 
vomiting, constipation, and prolonged hospital stays.  
Purpose: This independent study is meant to evaluate the current evidence regarding 
intraoperative lidocaine infusions. After a thorough review, the goal is to promote the use of 
lidocaine infusions to decrease postoperative pain scores, reduce the need for opioids, and 
increase patient satisfaction.   
Process: A literature review was conducted using the electronic databases CINAHL and 
PubMed through the University of North Dakota Health Sciences Library. Additional studies in 
reference lists of meta-analyses and randomized controlled trials were also retrieved. Articles 
were only included in this literature search if they were published in 2010 or after.    
Results: Intravenous lidocaine has been shown to decrease postoperative pain scores 
predominantly in patients undergoing abdominal surgery. Intravenous lidocaine infusions should 
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be considered a pharmacologic adjunct to achieve enhanced recovery after surgery and allow for 
decreased use of opioids intraoperative and postoperative as well.  
Implications: In particular surgical populations, utilizing lidocaine infusions intraoperatively 
can reduce pain scores, decrease the use of postoperative opioids and acquired side effects, and 
increase patient satisfaction. The findings are promising, but further research is indicated. 
Keywords: lidocaine, pain, infusion, intraoperative  
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Intraoperative Lidocaine Infusions for Postoperative Pain Management 
Background 
Approximately 80% of patients undergoing a surgical procedure experience postoperative 
pain. Although a certain degree of pain is expected, less than half report adequate pain relief after 
surgery. Of those patients without adequate pain relief, 10 to 50% percent of patients will 
develop chronic pain (Academy of Integrative Pain Management, 2018). For anesthesia 
professionals, pain control intraoperatively and postoperatively is of high priority, but not always 
easy to accomplish. Traditionally, surgical pain has largely been treated with opioids, and 
although there is beneficial use for these medications in surgery, opioids also produce many 
unwanted side effects such as respiratory depression, nausea and vomiting, constipation, 
delirium, and sedation. Unfortunately, these side effects can lead to increased hospital length of 
stay, increased costs, and overall patient dissatisfaction.  
Current research seeks to mitigate those unintended side effects through multi-modal 
analgesia and targeting various pain pathways and receptors with opioid sparing effects. 
Perioperative lidocaine infusions represent one piece of multi-modal anesthesia and have been 
shown to decrease pain in the post-surgical patient and decrease opioid requirements. Some 
studies have failed to demonstrate that lidocaine has any added benefit in treating postoperative 
pain in select surgical populations, however the purpose of this presentation is to highlight 
studies that offer strong evidence regarding lidocaine’s use as an analgesic adjunct. This analysis 
is meant to provide anesthesia professionals with a thorough review of intraoperative lidocaine 
infusions and evidence-based recommendations to enhance treatment of pain, improve surgical 
outcomes, and ultimately increase patient satisfaction. 
 
INTRAOPERATIVE LIDOCAINE INFUSIONS   6 
 
Case Report 
This case report involved a 43-year-old, 140 kg, 173 cm, Caucasian male patient who 
presented for an elective laparoscopic gastric bypass Roux-en-Y surgery. Past medical history 
was significant for obstructive sleep apnea (on home CPAP), asthma, hypertension, 
hyperlipidemia, gastric esophageal reflux disease, morbid obesity (BMI 46.5), and type 2 
diabetes. Previous surgical history included laparoscopic adjustable gastric band surgery with 
removal, hernia repair, and hand surgery. Current home medications included budesonide-
formoterol 160-4.5 mcg/puff inhaler used twice daily, hydrochlorothiazide 50 mg daily, losartan 
100 mg daily, and a multivitamin daily. Current laboratory values were reported to be within 
normal limits with the exception of a mild increase of Hgb A1C at 6.3 and creatinine 1.16. Chest 
x-ray and EKG were normal.  
Physical findings revealed a morbidly obese male who was assigned an ASA physical 
status class 3 primarily due to his body habitus. Vital signs were within normal limits. Cardiac 
exam was normal with a regular rhythm, no murmurs or rubs, breaths sounds were clear, and his 
mental status was alert and oriented. Pre-anesthetic evaluation included a Mallampati 3 airway, 
short neck with full neck range of motion, small mouth opening with adequate jaw protrusion, 
and no dental history. The patient was NPO for greater than 8 hours. Previous anesthesia records 
were reviewed and there was no history of previous airway management issues or anesthetic 
complications.   
Preoperatively, a scopolamine patch and gabapentin 600 mg were administered. A 20- 
gauge peripheral IV was placed and an infusion of lactated ringers was initiated. The patient was 
transported to the operating room and placed supine on the operating table with a wedge ramp. 
Standard monitors consisting of 5-lead EKG, blood pressure, oxygen saturation, and end-tidal 
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CO2 detection sampling were applied. Pre-oxygenation was administered using 100% FiO2 via 
mask for approximately 5 minutes. General anesthesia was induced with intravenous midazolam 
2 mg, fentanyl 100 mcg, lidocaine 140 mg, rocuronium 5 mg, propofol 250 mg, ketamine 30 mg, 
and succinylcholine 140 mg. The video laryngoscope was electively used because of his small 
mouth opening. A grade 1 view was obtained, and a size 8 endotracheal (ETT) was passed 
without difficulty. ETT placement was further verified using end-tidal CO2 monitoring and lung 
auscultation. Due to the patient’s asthma history, 3 puffs of albuterol were administered via the 
ETT after intubation. The patient was placed on volume control ventilation and general 
anesthesia was maintained with desflurane at 6% with a mixture of 1L/min oxygen and 1L/min 
air. A dexmedetomidine infusion was initiated after intubation with a bolus of 50 mcg over 10 
minutes with a continuous infusion at 0.5 mcg/kg/hour. A continuous lidocaine infusion was 
added at 2 mg/min following induction but prior to incision. The patient also received 
magnesium 2 g, acetaminophen 1 g IV, enoxaparin 40 mg, and cefazolin 3 g prior to incision. No 
additional doses of narcotics were used intraoperatively.  
Abdominal muscle relaxation was required, and multiple paralytic doses of rocuronium 
were given without effect. This warranted switching to cisatracurium 2 mg bolus doses, and 
adequate muscle relaxation was achieved. Intraoperatively, the patient required multiple doses of 
phenylephrine and ephedrine, and a phenylephrine infusion was started. The patient also received 
dexamethasone 4 mg after induction and ondansetron 4 mg at the end of the case. The lidocaine 
and dexmedetomidine infusions were stopped when the surgeon began closing the abdomen. The 
patient was fully reversed after surgical closure with glycopyrrolate 0.4 mg and neostigmine 5 
mg. Ketorolac 30 mg was given prior to extubation. After paralytic reversal and spontaneous 
breathing effort on the ventilator, the patient was extubated 284 minutes after incisional cut time 
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without difficulty. A nasal cannula was applied with 4 L oxygen, and the patient was transferred 
to the PACU. There was minimal EBL, and the patient received a total of 1800 ml of lactated 
ringers. In the recovery room, fentanyl 50 mcg was given twice for moderate pain, and a fentanyl 
PCA was initiated at 10 mcg/10min with no continuous rate. The patient was also started on 
scheduled ketorolac 30 mg every six hours.  
Later that afternoon on the inpatient unit, the patient was found to be resting comfortably, 
pain rated at 4/10. The patient had been out of bed and walking to the bathroom. The patient’s 
vital signs were WNL, and patient was not SOB or in any acute distress. His abdomen was soft, 
distended, and slightly tender to palpation. According to the chart, on POD 1, the patient 
continued to rate his pain 4/10, reported to have slept well, was ambulating in the halls, passing 
gas, and his PCA had been discontinued. There had been no increase in his PCA rate. The patient 
remained on scheduled ketorolac and prn oxycodone and was discharged on POD 2.    
Literature Search 
Method 
 A literature search regarding intraoperative lidocaine infusions was performed through 
the University of North Dakota’s Health Science Library using the following terms: (lidocaine 
AND infusion AND pain AND intraoperative). Electronic databases included CINAHL and 
PubMed. When using the above keywords, 15 articles were found in CINAHL. In PubMed, 
lidocaine was entered into the MESH database, the same keywords were added to the search, and 
23 articles were found in PubMed. Of those articles, 8 articles were used in this literature review. 
Additional studies were retrieved from reference lists of meta-analyses and randomized 
controlled trials. The literature search of randomized control trials and meta-analyses was limited 
to 2012 to the present date.  
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Discussion 
Pain Pathway 
In order to understand the role of local anesthetics in pain management, it is imperative to 
dive into the elements of the pain pathway. The International Association for the Study of Pain 
(IASP) defined pain as “an unpleasant sensory and emotional experience associated with actual 
or potential tissue damage” (2018). The first stage of the pain pathway involves pain 
transduction, which occurs when a noxious stimulus is transformed into an action potential. This 
occurs when specialized sensory receptors, called nociceptors, respond to noxious stimuli and an 
electrical impulse is generated. Nociceptors are found on A-delta and C nerve fibers, meaning 
they are the primary nerve fibers that are responsible for conducting pain to the brain. These 
nerve fibers are distributed in skin, viscera, muscles, joints, and meninges (Reddi & Curran, 
2013). A-delta nerve fibers have a large diameter, are lightly myelinated and conduct nerve 
impulses rapidly, while C fibers have a smaller diameter, are unmyelinated, conduct nerve 
impulses slowly, and innervate visceral internal organs (Nagelhout & Elisha, 2018). When a 
noxious stimulus is sensed, it causes a release of chemical mediators and neurotransmitters such 
as substance P, glutamate, bradykinin, histamine, serotonin, prostaglandins, and cytokines. These 
mediators and neurotransmitters directly stimulate peripheral nociceptors and cause an influx of 
sodium ions to enter the nerve fiber membrane and create depolarization. This creates an action 
potential and pain is generated (Nagelhout & Elisha, 2018). Once the action potential is 
generated, it is carried from the periphery to the central nervous system. Local anesthetics take 
effect at the beginning of the pain pathway and prevent the conversion of noxious stimuli into an 
action potential. In this way, the sensory input cannot be transmitted to the brain, and 
consequently analgesia occurs (Nagelhout & Elisha, 2018).  
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The second stage of the pain pathway involves pain transmission. The spinothalamic 
track is a pathway that transports pain signals from the trunk and lower body via the first, 
second, and third-order neurons. Primary afferent neurons are responsible for detecting noxious 
stimuli and moving the sensory input from the nociceptors to the gray matter of the dorsal horn 
in the spinal cord. The dorsal horn can be divided into ten layers called Rexed Laminae. A-delta 
and C fibers transfer information in Rexed lamina 1 and 2, in addition to projections to other 
laminae. First and second-order neurons connect in the dorsal horn, and second order neurons are 
responsible for transmitting pain signals from the spinal cord to the brainstem in the contralateral 
spinothalamic tract. Third order neurons conduct pain impulses from the brain stem to the 
thalamus, cortex, and higher levels of the brain and terminate in the somatosensory cortex where 
the perception of pain occurs. Third order neurons also have an important role in the descending 
inhibitory pain pathway (Reddi & Curran, 2013). There is a synaptic cleft between the ends of 
nerve fibers and the dorsal horn neurons. Excitatory neurotransmitters such as glutamate, 
substance P, bradykinin, and nitrous oxide are released to transmit the pain impulses across the 
synaptic cleft. Then the pain signals are transmitted from the spinal cord to the brain stem and 
thalamus via the spinothalamic pathway. The third stage of the pain pathway occurs when pain 
impulses reach the thalamus and pain is processed (Kumar, Gupta, Kaleem, & Pandey, 2014).   
The fourth stage in the pain pathway involves pain modulation. Modulation involves 
altering neural afferent activity such as pain inhibition or enhancing of the pain signal. Pain is 
altered along the descending pain pathway in the location of the periaqueductal grey (PAG) in 
the midbrain (Reddi & Curran, 2013). The PAG contains a high concentration of endogenous 
opioids and other inhibitory neurotransmitters such as serotonin, acetylcholine, and oxytocin 
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which serve as a natural way to “turn off” pain (Kumar, Gupta, Kaleem, & Pandey, 2014). Many 
analgesia pharmaceuticals such as opioids occur at this component of the pain pathway.  
Lidocaine  
Mechanism of Action  
After reviewing the physiology of the pain pathway, lidocaine’s mechanism of action can 
be delineated. Intravenous lidocaine is known to have analgesic, anti-inflammatory, and anti-
hyperalgesia properties, but its role in pain begins at the cellular level. Lidocaine produces 
analgesia through the involvement of sodium channel blockade, acetylcholine in cerebral spinal 
fluid, NMDA receptors, and by reducing inflammatory responses. Lidocaine contains an 
aromatic ring with an amine at opposite ends of the molecule and is separated by a hydrocarbon 
chain and an amide bond. This amide bond structure classifies lidocaine as an amide local 
anesthetic. Lidocaine’s primary mechanism of action involves binding to the peripheral and 
central voltage gated sodium channel’s inner core of the alpha subunit (NYSORA, 2019a).  
Sodium channels help maintain an electrical gradient across the neuronal cell membrane, 
initiate and facilitate action potentials, and are required for transmission of peripheral 
nociceptive stimuli to reach the brain. Sodium channels can exist in “resting,” “open,” and 
“inactivated,” states, and supply both skeletal and cardiac muscle and neuronal tissue. At rest, 
sodium channels are in the closed state, and sodium ions are highly concentrated in the 
extracellular space. When an action potential occurs, neuronal sodium channels quickly open 
which allows extracellular sodium to enter the cell, making the inside of the cell positive and 
depolarization occurs (NYSORA, 2019a). Anesthesia occurs when lidocaine (along with all local 
anesthetics) binds to sodium channels, prevents the sodium influx and action potential, and 
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results in conduction blockade and a selective depression of pain transmission in the spinal cord 
so the brain cannot sense painful stimuli (Yon et al., 2013 & Peng et al., 2016).  
When lidocaine is administered intravenously, it also increases the amount of 
acetylcholine in the cerebrospinal fluid. This increase in acetylcholine inhibits the descending 
pain pathway resulting in analgesia. It is thought that lidocaine contributes to a release of 
endogenous opioids and an inhibition of the excitatory neurotransmitter glycine (Ibrahim, Aly, & 
Farrag, 2018).  
Lastly, lidocaine has potent anti-inflammatory effects by inhibiting the N-methyl-d-
aspartate (NDMA) receptor. Noxious events, such as surgery, create hyperexcitability in the 
NMDA receptors and the release of cytokines in the central nervous system.  When lidocaine 
blocks NMDA receptors, there is an inhibition of inflammatory mediators and a decrease in the 
post-synaptic depolarization which results in decrease of pain signaling to the brain. When 
lidocaine can reduce cytokine production, there is a decreased inflammatory response, less 
windup of pain, and a decreased risk for hyperalgesia (Ibrahim, Aly, & Farrag, 2018). 
Additionally, when lidocaine reduces the inflammatory processes in the bowel by inhibiting 
cytokine secretion, there is a more rapid return of bowel function on top of decreased pain.  
Along with lidocaine’s unique role in pain, it also has a short half-life and favorable 
safety profile compared to esters, which makes it the local anesthetic of choice for intravenous 
administration. Lidocaine has a rapid onset of approximately 45-90 seconds, and the initial half-
life for bolus administration is approximately 10 minutes due to rapid liver metabolism and 
redistribution (Gordon & Schroeder, 2008). When lidocaine infusions are discontinued, plasma 
levels decrease quickly. With a continuous infusion, the half-life is estimated to be about 1.5 to 2 
hours, and in healthy patients there is no drug accumulation (Eipe, Gupta, & Penning, 2016). 
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Lidocaine is metabolized in the liver and clearance is highly dependent on hepatic blood flow 
and enzyme function. Lidocaine should be used with caution in patients with decreased hepatic 
blood flow, such as in heart or liver failure or patients taking cytochrome inhibitor medications. 
Likewise, renal failure increases volume of distribution of amide local anesthetics and can 
increase metabolic by-products (NYSORA, 2019a). Ultimately, dosages should be reduced by 
50% in patients older than 70 years of age or with liver disease, in order to avoid complications 
such as CNS depression, seizures, drowsiness, bradycardia, and hypotension (Gordon & 
Schroeder, 2008).  
Side Effects 
Although side effects from a lidocaine infusion have been shown to be of low risk, it 
remains vital for anesthesia practitioners to be aware of complications and signs of toxicity. Mild 
symptoms, often associated with low lidocaine plasma concentrations, consist of restlessness, 
tinnitus, circumoral numbness, vertigo, or tremors. More serious side effects include drowsiness, 
hypotension and tachycardia, and can progress to bradycardia, arrythmias, seizures, 
unconsciousness, coma, and cardiovascular collapse. According to NYSORA, “most local 
anesthetics will not cause cardiovascular toxicity until the blood concentration exceeds three 
times that necessary to produce seizures” (2019b).  
Intraoperative Use of Lidocaine 
Benefits from intraoperative lidocaine infusions have been controversial, however there 
has always been success reported in the abdominal surgical population. The first study involves a 
prospective, double-blind, placebo-controlled trial using 36 patients undergoing subtotal 
gastrectomies who received a lidocaine infusion with a bolus dose of 1.5 mg/kg followed by a 
continuous infusion of 2 mg/kg/hour. The study showed that these patients had lower pain scores 
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24 hours after surgery, and fentanyl consumption was significantly lower in this group until 12 
hours postoperatively compared to a normal saline placebo infusion. No differences were found 
related to nausea or hospital length of stay (Yon, Choi, Kang, Park &Yang, 2013). Two years 
later, another randomized, double-blind, placebo-controlled study was conducted. This study 
included 50 patients undergoing scheduled laparoscopic colectomies and found similar results. 
The same lidocaine dose was used as above, and again, patients in the lidocaine group reported 
significantly lower pain scores 24 hours postoperatively and required significantly less fentanyl 
until 12 hours after surgery compared to a normal saline placebo group. Patients receiving 
lidocaine infusions in this study also had fewer complaints of nausea and higher recovery 
satisfaction scores (Ahn et al., 2015). In both studies, patients in the lidocaine groups were found 
to have lower C-reactive protein levels postoperatively signifying that lidocaine possesses anti-
inflammatory properties. It is also important to note that none of the patients in either the 
lidocaine or placebo group received pre-medications or any additional analgesics intraoperatively 
other than lidocaine (Ahn et al., 2015 & Yon et al., 2013). 
The use of intraoperative lidocaine has also been studied in patients undergoing bariatric 
surgery. A prospective randomized, double-blind, placebo-controlled clinical trial consisting of 
50 patients undergoing laparoscopic bariatric surgery was reviewed. The study found that when 
an intraoperative lidocaine infusion was used with a bolus of 1.5 mg/kg followed by a 2 
mg/kg/hour infusion, patients reported higher postoperative quality of recovery scores, had lower 
postoperative opioid requirements, and fewer complaints of nausea when compared to a normal 
saline placebo group. Patients in both groups were pre-medicated with 0.04 mg/kg IV midazolam 
and given propofol 1-2 mg/kg, remifentanil 0.1 mcg/kg/min IV infusion, and succinylcholine 1-2 
mg/kg for induction. Anesthesia maintenance was controlled with remifentanil titrated to 20% of 
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blood pressure baseline with desflurane titrated to a BIS of 40-60, and rocuronium. When 
laparoscopic instruments were removed, hydromorphone 0.01 mg/kg was given. Multi-modal 
analgesic techniques may be most important in this morbidly obese patient population because 
opioids are often accompanied by adverse respiratory complications such as hypoventilation and 
hypoxemia which can complicate postoperative recovery (De Oliveira Jr. et al., 2013).  
Multiple randomized controlled trials have also discovered the significant impact 
intravenous lidocaine infusions have on laparoscopic cholecystectomy patients. A randomized, 
blinded, placebo-controlled trial of 71 patients concluded that when using a lidocaine bolus of 
1.5 mg/kg before skin incision followed by an infusion of 2 mg/kg/hour, patients in the lidocaine 
group reported significantly lower pain scores compared to the normal saline placebo group at 2 
hours and 6 hours postoperatively. Additionally, participants in the lidocaine group had 
significantly longer times for the request of the first dose of analgesic compared to the normal 
saline group, and the total mean analgesic requirements after surgery were significantly less. 
This study also found that times to first flatus and bowel movement were significantly shorter in 
patients who received lidocaine. This is noteworthy considering abdominal surgery patients often 
have complications such as ileus, nausea, vomiting, and constipation. This particular study also 
measured concentrations of inflammatory markers such as serum IL-6, IL-8, IL-1ra before 
induction of anesthesia, at the end of surgery, and at 12 hours postoperatively. It was found that 
the levels of serum IL-6 and IL-8 in the lidocaine group at the end of surgery and 12 hours 
postoperatively were lower than the control group, reaffirming that lidocaine exhibits an anti-
inflammatory quality which could be responsible for the decreased times for return of bowel 
function (Song, Sun, Zhang, Li, & Yang, 2017).  
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A meta-analysis of 5 randomized controlled trials involving 274 patients was conducted 
on patients undergoing laparoscopic cholecystectomies who also received intravenous infusions 
of lidocaine for pain management. Of the 5 reviewed trials, 4 trials used a lidocaine bolus of 1.5 
mg/kg followed by a continuous infusion of 2 mg/kg/hour, and 1 trial used a lidocaine bolus of 
1.5 mg/kg but increased the continuous rate to 3 mg/kg/hour. The meta-analysis found that the 
lidocaine infusion group had significantly lower pain scores at 12 hours, 24 hours, and 48 hours 
after surgery. Patients in the lidocaine group were also found to have reduced opioid 
consumption and fewer adverse effects (Zhao et al., 2018).  
Lastly, a double-blind, placebo-controlled study with 45 participants found that when 
using a lidocaine bolus of 1 mg/kg on induction followed by a 2 mg/kg/hour infusion for patients 
undergoing laparoscopic gynecological procedures, patients had decreased analgesic 
requirements, but the trial failed to achieve statistical significance when compared to the normal 
saline placebo group. However, the patients receiving lidocaine has a significantly decreased 
time to first flatus (Grady, Clark, Lenahan, Oudekerk, Hawkins, Nezat, Pellegrini, 2012). This is 
one of the few studies that utilized a lidocaine bolus of only 1 mg/kg, and it must be questioned 
if this decrease in bolus dose could possibly affect outcomes.  
There is substantial evidence that supports the use of lidocaine infusions to decrease 
postoperative pain in patients with abdominal surgeries, and other surgical populations have also 
experienced positive effects. Intraoperative lidocaine has also proved to be effective in patient 
populations undergoing spinal fusion surgery, supratentorial brain tumor surgery, 
laminectomy/discectomy, and mastectomies. A recent prospective, randomized, double-blinded 
study involving a total of 40 patients undergoing spinal fusion surgery demonstrated that 
administering a lidocaine bolus of 2 mg/kg before induction followed by a continuous rate of 3 
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mg/kg/hour until the end of surgery reduced the postoperative pain scores for up to 3 months, 
reduced morphine consumption in the first 24 hours postoperative, and prolonged the time to 
first request for additional pain medication compared to a normal saline placebo group. In this 
study, all participants received an anesthesia regimen of propofol, Cisatracurium, isoflurane, 
ketorolac, fentanyl, and acetaminophen in equal doses (Ibrahim, Aly, & Farraq, 2018).  
In patients having supratentorial brain tumor surgery, it was found that lidocaine 
significantly decreased the proportion of patients with acute pain in the PACU. A prospective, 
randomized, double-blinded study with 80 patients found that when using an intraoperative 
lidocaine with a bolus of 1.5 mg/kg after induction and an infusion of 2 mg/kg/hour until the end 
of surgery, the incidence of “no pain” was higher in the lidocaine group than the normal saline 
placebo group prior to transferring out of the PACU. There were no patients with moderate or 
severe pain in either group Anesthesia between the groups also consisted of using midazolam 
0.05 mg/kg for premedication followed by Sufentanil 0.2 mcg/kg, propofol 1.5-2.5 mg/kg, and 
rocuronium 0.6 mg/kg for induction. Anesthesia was maintained using propofol, sevoflurane, 
and a remifentanil infusion (Peng et al., 2016). Opioid sparing effects in this neuro-surgical 
population are even more important as surgeons often require neurological assessments 
immediately after surgery.  
Lidocaine has also been shown to decrease pain and reduce the consumption of opioids in 
patients undergoing laminectomy and discectomy lumbar surgery. A prospective, randomized, 
double-blinded, and placebo-controlled clinical trial using 51 subjects agreed that lidocaine 
infusions contribute to decreased postoperative pain scores, reduced fentanyl consumption, and 
decreased length of stay when compared to a normal saline placebo group. The lidocaine bolus 
was given at 1.5 mg/kg and the infusion was dosed at 2 mg/kg/hour until the end of surgery. The 
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2 groups received the same anesthetic protocol, which consisted of thiopental 5 mg/kg and 
rocuronium 0.6 mg/kg for induction. Anesthesia was maintained using 2 to 3% sevoflurane with 
1.5 L/min nitrous oxide and 1.5 L/min O2 mixture. No premedications were given. There is no 
note of any opioids or other analgesics being administered intraoperatively. The lidocaine group 
reported less pain than the normal saline group for up to 48 hours, and the patients also had a 
decreased hospital length of stay (Kim et al., 2014).  
Lastly, lidocaine infusions have been shown to improve postoperative quality of 
recovery, reduce intraoperative opioid requirements, and improve chronic pain for patients 
undergoing mastectomy for breast cancer. A prospective, double-blind, randomized clinical trial 
using 116 female patients utilized a lidocaine bolus of 2 mg/kg after induction followed by an 
infusion of 2 mg/kg/hour. The study compared intraoperative lidocaine, magnesium, and normal 
saline groups. Magnesium is being incorporated into anesthesia as another multi-modal 
technique because it is also a NMDA receptor antagonist and has anti-nociception mechanisms. 
The intraoperative magnesium was initiated with a bolus of 20 mg/kg followed with a continuous 
infusion of 20 mg/kg/hour. The intraoperative lidocaine group had favorable effects on early 
postoperative recovery and higher quality of recovery scores when compared to the magnesium 
and normal saline groups.  The quality of recovery survey included dimensions such as physical 
comfort, emotional state, physical independence, psychological support, and pain. The study also 
showed that lidocaine and magnesium did not have significant differences in reducing 
intraoperative opioid consumption, but they both proved superior to normal saline infusions 
(Kim et al., 2017).  
While many reputable trials appear to decrease postoperative pain scores and reduce 
opioid requirements, lidocaine’s use in other surgical procedures can be controversial. Each 
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surgery possesses a different level of triggered pain and may alter the effects of lidocaine. 
Although the previously mentioned study argues that lidocaine infusions can be effective for 
mastectomy patients, a study published in the same year disagrees. In this particular trial, it was 
found that there were no differences in quality of recovery, pain scores, or opioid consumption 
for mastectomy patients at periods of 24 hours post operation up to 6 months. The study 
examined 148 patients who were randomly divided into 2 groups. One group received 1.5 mg/kg 
bolus of IV lidocaine followed by an infusion of 2 mg/kg/hour, and the placebo group received a 
normal saline bolus and infusion at the same rates. Each group received identical anesthetic 
regimens of propofol, sevoflurane, remifentanil infusions, and hydromorphone at the end of 
surgery. It was found that pain burden, opioid consumption, and quality of recovery were no 
different at 24 hours postoperative when comparing the lidocaine and normal saline groups 
(Kendall et al., 2017). Although this study includes recent data, all surgical study participants 
received intraoperative opioid medications which could affect the validity of the study when 
compared to studies that do not use any additional opioids. One must question whether the 
lidocaine infusion would show any benefit when compared to normal saline if the patient is 
already well narcotized.  
Another study argued that lidocaine infusions are not effective for mastectomy patients. 
A 2016 meta-analysis of randomized control trials found that lidocaine infusions did not affect 
postoperative pain scores at rest or activity 2 hours to 3 days when compared to a placebo of 
normal saline. However, at 72 hours postoperative, the lidocaine group required fewer 
analgesics. There was also a trend of lower pain scores in the lidocaine group at 2 hours 
postoperative and 48 hours, but the evidence was not statistically significant. The meta-analysis 
included a total of 84 patients randomized to the lidocaine group, and 83 patients randomized to 
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the placebo group. The study concluded that lidocaine may produce more significant benefits in 
patients undergoing abdominal surgery because the intensity of pain is higher than many other 
surgeries that have been studied (Chang et al., 2016).  
When comparing all of the above studies to the patient in the case report, it was found 
that the majority of studies used a lidocaine bolus of 1.5 mg/kg followed by a continuous 
infusion of 2 mg/kg/hour. The case report patient received a lidocaine bolus of 1 mg/kg during 
induction followed by a continuous infusion of 2 mg/min, which was not weight based and 
underdosed based on the patient’s body weight. In addition to a lidocaine infusion, the case 
report patient also received preoperative acetaminophen and gabapentin and other multi-modal 
agents in surgery including ketamine, magnesium, a dexmedetomidine infusion, and ketorolac, 
which all could have contributed to his recovery. Many reviewed studies did not include other 
multi-modal medications when testing the efficacy of lidocaine. Like the studies regarding 
abdominal surgery, the case report patient had well controlled pain and limited narcotic use 
postoperatively. Additionally, the case report patient did not have preoperative or postoperative 
C-reaction protein levels drawn so the inflammatory response could not be assessed.  
Even though most studies used a consistent lidocaine dose, many studies were vague 
regarding when the lidocaine bolus was started, how long the bolus infused, and precise times for 
infusion discontinuation which could affect outcomes. In most studies, it was standard for 
postoperative patients to receive a narcotic PCA. Although this may seem counterintuitive, only 
demand dosing was ordered and significantly less total narcotic PCA was required in the 
lidocaine groups (Ahn et al., 2015, De Oliveira Jr. et al., 2013, Kim et al., 2014, Peng et al., 
2016, & Yon et al., 2013). Most studies assessed patients’ pain using a Visual Analog Scale 
(VAS) with 0 meaning “no pain” and 10 meaning the “worst possible pain”. Pain was evaluated 
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at slightly different intervals, but common times included 0, 2, 4, 8, 12, 24, and up to 48 hours 
post-surgery. Most studies collected data regarding lidocaine’s effect on postoperative pain 
scores, time until request for first pain medication, and total opioid dosing postoperatively (Ahn 
et al., 2015, De Oliveira Jr. et al., 2013, Khan et al., 2016, Kim et al., 2014, Kim et al., 2017, 
Peng et al., & Yon et al., 2013).  
One inconsistency that was noted while reviewing the literature was that studies failed to 
describe whether lidocaine should be dosed per total body weight, ideal body weight, or adjusted 
body weight. For the patient in the case report, total body weight was used for dosing. A 
lidocaine bolus of 140 mg was given but only a 1 mg/kg calculation was used. The patient 
received a continuous lidocaine infusion at 2 mg/min (120 mg/hour) instead of the recommended 
2 mg/kg/hour. If 2 mg/kg/hour would have been used and based on TBW, the continuous dose 
would have increased from 120 mg/hour to 280 mg per hour. A dose of 2 mg/min would 
underdose a patient as long as they weigh over 60 kg. De Oliveira Jr. et al. (2013) is the only 
study that advises using adjusted body weight (ABW) for dosing lidocaine infusions. The 
calculation is [ideal body weight (IBW) + 0.4 x (actual body weight- IBW)]. This is an important 
consideration when dosing lidocaine infusions because a dose based on TBW can easily be 
doubled compared to IBW, especially for obese patients.   
Maximum Safe Doses 
In order to safety administer intravenous lidocaine infusions, it is imperative anesthesia 
professionals understand how to calculate maximum dosages for lidocaine infusions and other 
possible local anesthetics used by the surgeon.  The maximum dose for plain lidocaine is 4 
mg/kg and increases to 7 mg/kg if epinephrine is added. It is important to remember that the 
overall maximum dose for lidocaine is 300 mg, even if the dose per kilogram exceeds this. The 
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maximum dose is also calculated as a “per hour” guideline, which means each hour an additional 
300 mg can be given safely. For example, if the patient is 75 kg and a bolus of 1.5 mg/kg (112.5 
mg) and infusion of 2 mg/kg/hour (150 mg) is used, theoretically the patient would receive 262.5 
mg after the first hour. The lidocaine bolus is often given during induction and takes the place of 
a bolus given to relieve propofol induced pain or to blunt the SNS response of airway 
manipulation with intubation. After the first hour, a continuous infusion rate of 2 mg/kg/hour 
would equal 150 mg for this patient of 75 kg. This would mean the patient is receiving 50% of 
the local anesthetic maximum dose, therefore the surgeon is able to use 50% of the maximum 
dose of local anesthetic for skin infiltration at the end of surgery. For example, if the surgeon 
injects 0.25% bupivacaine with epinephrine during incision closure, the maximum dose is 3 
mg/kg. The patients calculated max dose for bupivacaine is 225mg, and 50% of that is 112.5 mg. 
In order to calculate the amount in milliliters, the dose must be divided by the local anesthetic 
concentration. If the local anesthetic is 0.25% bupivacaine, 45 ml can still be injected safely. 
Additionally, when calculating maximum doses, it can be theorized that a continuous infusion is 
constantly being metabolized at a steady rate, meaning at the end of each hour, not all of the 
local anesthetic is adding up at one time.  
In some cases, local anesthetics can reach their maximum doses quickly which poses a 
greater risk for lidocaine toxicity, however none of the articles found evidence to support this 
fear. Specifically, authors noted that no blood samples showed toxic levels and no cardiovascular 
or neurological adverse events occurred (Ahn et al., 2015, De Oliveira Jr. et al., 2013, & Peng et 
al., 2016). Lidocaine toxicity is likely to be seen at plasma concentration of 5mcg/ml. However, 
when a bolus of 1-2 mg/kg is administered and then followed with a continuous infusion of 1.5 
mg/kg, the corresponding plasma concentration is only at 2 mcg/ml, and the risk of toxicity is 
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low (Lauretti, 2008). In this way, practitioners need to be aware of lidocaine toxicity, risks, and 
treatment, however, lidocaine infusions have a favorable safety profile and should not be avoided 
because of the fear of overdosing.  
Although reaching critical levels with lidocaine infusions is rare, it remains imperative 
for anesthesia professionals to be aware of local anesthetic systemic toxicity (LAST) and 
treatment options. Variables that increase the risk of LAST include using the wrong local 
anesthetic drug or dosage, extremes of age, patient comorbidities, small muscle mass, liver or 
kidney failure, and malnutrition. Side effects of local anesthetics and more serious signs of 
LAST are mentioned previously. In terms of LAST, prevention is key. It is imperative to know 
maximum safe doses, use proper monitoring, careful selection of local anesthetic and attention to 
concentration, and have adequate preparation for possible resuscitation (Nagelhout & Elisha, 
2018).  
Treatment of LAST involves the need for immediate recognition followed by seizure 
management, advanced cardiac life support (ACLS) and prompt administration of 20% lipid 
emulsion. The local anesthetic should be stopped, and one should seek help. Benzodiazepines are 
the first line treatment for seizure activity. If patients are unstable, airway management and 
circulatory support is required (NYSORA, 2019b). Reversal of LAST is treated with lipid 
emulsion and CV collapse will occur if lipids are not administered. If the patient weighs greater 
than 70 kg, a 20% lipid emulsion bolus of 100 ml bolus is given over 2-3 minutes followed by an 
infusion of 200-250 ml over 15-20 minutes. If patients remain unstable, bolus doses can be 
repeated twice, and infusion rates can be doubled. If the patient weighs less than 70 kg, a bolus 
dose of 1.5 mg/kg is given followed by an infusion of 0.25 ml/kg/min until symptoms resolve. 
There is a dosing limit of 12 ml/kg which is particularly important in the small child. After a 
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LAST incident, patients should be continuously monitored 4-6 hours after a cardiovascular event 
or at least 2 hours after a CNS event. There is a LAST algorithm that should be available and 
familiar to anesthesia providers who administer local anesthetics (American Society of Regional 
Anesthesia and Pain Medicine, 2018).  
Practice Recommendations 
After completing a thorough literature review, there are two main practice 
recommendations. First, anesthesia professionals should consider the use of lidocaine infusions 
with a bolus and continuous infusion for any abdominal surgery. According to the most current 
literature, the recommended intravenous infusion should include an initial bolus of 1.5 mg/kg 
followed by an infusion of 2 mg/kg/hour (Zhao et al, 2018). The lidocaine infusion bolus should 
be initiated immediately prior to induction and followed by a continuous infusion until wound 
closure. A bolus is always recommended because a continuous infusion alone will take 4-8 hours 
to achieve stead state plasma concentration which is often much longer than common surgical 
times (Eipe, Gupta, & Penning, 2016). Other opioids can be used intraoperatively and 
postoperatively, but practitioners may find that less opioids are required. Lidocaine infusions 
should be predominantly considered for patients undergoing abdominal surgery because data is 
most consistent with this specific population. Additionally, the infusions should be reserved for 
cases greater than one hour where larger amounts of opioids are generally needed.  
The second, and possibly most important recommendation, includes the need for further 
research in many areas. Additional high-quality studies need to be performed with larger sample 
sizes in order to continue to validate the current use of lidocaine. Further studies need to include 
comparisons regarding different lidocaine doses and timing of initiation and discontinuation of 
the infusion. Although most randomized controlled trials utilized a lidocaine bolus of 1.5 mg/kg 
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followed by a continuous infusion of 2 mg/kg/hour, the optimal perioperative treatment protocol 
is unknown. Lastly, there also needs to be further research conducted regarding dosing on TBW 
compared to IBW or ABW as a way to mitigate unnecessary side effects. 
Conclusion 
Pain is complex and an unwanted component of almost all surgical procedures. 
Intraoperative lidocaine administration should strongly be considered when formulating a multi-
modal approach to pain management within an anesthetic plan. Intraoperative lidocaine has 
proven to be a safe, valuable, and a cost-effective intervention that can decrease postoperative 
pain, reduce the use of opioids, and increase overall patient satisfaction.  
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